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Abstract Aims: Low-molecular-weight heparins are drugs of first choice for thromboprophy-
laxis in cancer surgery. We sought to determine the optimal use of bemiparin in cancer surgery
in standard clinical practice.
Patients and methods: A retrospective, multicentre audit on the use of bemiparin in patients
undergoing cancer surgery and given prophylaxis with bemiparin was undertaken. Surgeons’ as-
sessment of venous thromboembolic (VTE) risk (moderate or high) was compared to the crite-
ria of current Consensus Guidelines for VTE management. We assessed the incidence of
documented symptomatic VTE, bleeding events, thrombocytopenia, deaths and total events
related to VTE or bemiparin prophylaxis (i.e. bleeding, thrombocytopenia). The potential
economic impact of postoperative vs. preoperative bemiparin was also analysed.
Results: Clinical records from 197 patients from 5 Spanish centres were checked. Prophylaxis
was started postoperatively in 45 patients (22.8%). According to the surgeons’ criteria, 73
(37.1%) patients were at high VTE risk and received bemiparin 3500 IU/d. However, according
to the criteria of current Guidelines, 189 (95.9%) patients were at high risk of VTE (heteroge-
neity P-value< 0.0001). Three (1.5%) patients, all of them receiving bemiparin 2500 IU/d,
developed a symptomatic confirmed VTE. There were 4 major and 5 minor bleeding events dur-
ing bemiparin prophylaxis. A lower incidence of bleeding (2.2% vs. 5.3%; PZ 0.48) and total
events (2.2% vs. 9.9%; PZ 0.11) was seen with bemiparin started postoperatively as compared
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Bemiparin thromboprophylaxis in cancer surgery 115to preoperative bemiparin. Bleeding rates did not significantly differ between patients given
low or high bemiparin prophylactic doses (4.0% vs. 5.5%; PZ 0.72). Two patients died due to
cardio-respiratory failure and sepsis, respectively. Postoperative bemiparin provided net cost
savings of V909 per patient compared to preoperative start of prophylaxis due to shorter
hospital stays (9 vs. 11 days) and lower incidence of complications in the postoperative
bemiparin group.
Conclusions: Many cancer patients are still poorly assessed for risk of VTE. Bemiparin 3500 IU/d is
associated with a lower incidence of VTE without significant increase in complications as com-
pared with bemiparin 2500 IU/d. Postoperative bemiparin prophylaxis seems to be as effective
and safer than preoperative start of prophylaxis. Further prospective clinical studies are
needed to fully address this issue.
ª 2006 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.Introduction
Low-molecular-weight heparins (LMWH) are effective and
safe for prophylaxis of venous thromboembolism (VTE) in
surgical patients,1,2 and represent a thromboprophylactic
method of first choice.3,4
Cancer patients have an increased risk of both post-
operative VTE5 and bleeding during anticoagulant therapy6
compared to cancer-free patients. Without prophylaxis, the
overall prevalence of systematically detected deep vein
thrombosis (DVT) estimated by the fibrinogen uptake test
in cancer surgery is 35%.7 Compared to placebo, LMWH
prophylaxis provides relative risk reductions of 81% in veno-
graphic DVT, 71% in clinical VTE, 68% in fatal PE and 60% in
death by any cause.7e10 By contrast, major bleeding events
increase from 1.4% with placebo to approximately 3.0% in
patients receiving an LMWH,7e10 and to 8.1% with unfractio-
nated heparin (UFH) in cancer surgery.2 However, bleeding
usually follows a benign clinical course, and it seems rea-
sonable to give priority to pharmacological prophylaxis,
since mortality rates are significantly reduced. Therefore,
the use of new strategies to reduce bleeding rates in cancer
surgery should be encouraged.
Bemiparin (Hibor, Ivor, Zibor, and Badyket) is a new
‘‘second generation’’11 LMWH with a low bleeding tendency
that can be initiated pre- or postoperatively,11,12 without
compromising efficacy.11e13 Postoperative start of bemi-
parin prophylaxis should theoretically minimise the risk of
spinal haematoma and the perioperative bleeding rates.
Thus, it could be of great interest to compare pre- and
postoperative start of bemiparin prophylaxis, particularly
as regards the relative incidence of VTE and bleeding.
This study was designed to describe the patterns of use
of bemiparin in cancer surgery in standard clinical practice.
We also analysed the influence of bemiparin dose and
timing of first administration on clinical and economic
outcomes.
Study design and methods
This study was designed as a retrospective, multicentre,
cohort study. We checked clinical records from patients
who underwent surgery for cancer and had received
thromboprophylaxis with bemiparin. Since this was a retro-
spective audit of practice, there were no pre-established
exclusion criteria.Patients received open label prophylaxis with bemiparin
(Hibor, Laboratorios Farmace´uticos Rovi, Madrid, Spain) at
the daily subcutaneous dose of 2500 IU or 3500 IU, depend-
ing on the degree of risk according to surgeons’ criteria.
An additional stratification of thromboembolic risk was per-
formed based on the ACCP Consensus Conference3 and the
International Consensus Statement.4 According to these lat-
ter criteria, major cancer surgery in patients over 40 years
of age was considered high-risk surgery. Major cancer sur-
gery in patients under 40 years or minor cancer surgery in
patients over 40 years of age was considered as moderate
risk surgery. Risk assessment by the surgeons and risk factor
assessment based on current VTE Consensus Guidelines
were compared. Prophylaxis was maintained based on
investigator’s criteria, during the risk period or until full mo-
bilization of the patient. Data were recorded in 2 periods:
the first covered the hospitalisation time, and the second
period comprised the time from hospital discharge to the
first outpatient visit. We defined 2 types of cohorts: depend-
ing on the timing of first bemiparin administration (post- vs.
preoperative) and depending on the bemiparin dose used
(2500 IU vs. 3500 IU). Data on the dose and timing of first
bemiparin administration were extracted from the medica-
tion orders and medication administration records, which
were available from patients’ hospital medical records.
The efficacy and safety outcomes were calculated in differ-
ent cohorts (post- vs. preoperative, and 3500 IU vs. 2500 IU).
Finally, a potential correlation of the type of surgery or con-
comitant medication on bleeding rates was analysed.
Concomitant medications, including drugs that could
alter haemostasis (analgesics or anti-platelet drugs), and
use of non-pharmacological treatments, such as elastic
bandages or intermittent pneumatic compression devices,
were extracted from clinical records.
The outcomes collected were as follows: symptomatic
VTE (DVT and/or PE) confirmed by objective testing (Dopp-
ler ultrasound or ascending contrast venography for DVTand
high-probability lung scanning, pulmonary angiography for
PE, or necropsy in fatal cases); major bleeding (defined as
overt bleeding associated with a decrease in haemoglobin
levels by 2 g per decilitre or more or requiring transfusion of
2 or more units of packed red cells or whole blood, bleeding
requiring reoperation, fatal, retroperitoneal or intracranial
bleeding, or bleeding requiring treatment discontinuation);
minor bleeding (if it was overt but did not meet the other
criteria for major bleeding); moderate thrombocytopenia
(platelet count lower than 100,000 platelets per cubic
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than 50,000 per cubic millilitre); and deaths. We also ana-
lysed total events related to VTE or bemiparin prophylaxis
(i.e. bleeding, thrombocytopenia) in each cohort.
A minimisation cost analysis of preoperative versus post-
operative start of bemiparin prophylaxis was performed by
analysing the summary costs for treatment and complica-
tions derived from the study. Unit costs for treatments and
complications were adopted from the average wholesale
price of treatments14 and from published medical resource
cost data.15,16 The results were expressed in terms of costs
and incremental cost-differences. The study setting was
the Spanish National Health System. Thus, only direct med-
ical costs were included. The time horizon chosen was 40
days. Costs were given in euros for the year 2002, according
to the latest Spanish clinical and administrative data sources
available. Univariate sensitivity analyses were used to iden-
tify important model uncertainties.
Statistical analysis
Absolute risks of VTE, death, bleeding events and other
safety outcomes were shown. Subgroups were compared
depending on the dosage schedule (pre- vs. postoperative)
and the dose used (2500 IU vs. 3500 IU). A two-sided c2 test
or a Fisher exact test was used for qualitative variables,
and a Student’s test was used for quantitative variables.
A P-value of less than 0.05 was considered significant for
all statistical tests. These calculations were performed
using SPSS software, version 7.5.
Results
Study population
A total of 197 patients undergoing cancer surgery were
retrospectively included in the study in 5 Spanish centres
(see Appendix).
Demographic characteristics are shown in Table 1. Major
cancer surgery was performed in 189 patients (95.9%). The
most commonly involved organs were colon (50 cases),
rectum (39 cases), sigmoid (33 cases), stomach (16 cases),
lungs (13 cases), breasts (12 cases), urinary bladder and/or
ureters (13 cases), prostate (10 cases) and uterus and/
or ovaries (6 cases).
All the 197 patients were administered open label
prophylaxis with bemiparin (Table 1). Hospital stay was 2
days shorter in patients given postoperative bemiparin as
compared to those receiving the preoperative schedule
(9.0 vs. 11.0 days; median).
In the surgeons’ opinion, 124 (63%) patients had
a moderate risk of VTE and were therefore given
bemiparin 2500 IU/d, while 73 (37.1%) patients were at
high risk and received bemiparin 3500 IU/d. However, ac-
cording to the criteria of current VTE Consensus Guide-
lines, 189 (95.9%) patients were at high risk of VTE
(>40 years undergoing major cancer surgery) and 8
(4.1%) patients were at moderate risk of VTE (6 pa-
tients< 40 years and 2 patients undergoing minor cancer
surgery). Heterogeneity between investigators’ risk as-
sessment and the criteria of current VTE ConsensusGuidelines was statistically significant (heterogeneity P-
value< 0.0001), resulting in bemiparin under-dosage in
116 (59%) patients.
One hundred and four (52.8%) of the 197 patients were
given an analgesic agent for postoperative pain relief.
Metamizole was the most commonly used analgesic.
Table 1 Demographic data and baseline characteristics
Characteristic Total (NZ 197)
Age e yr.
Median 70
Range 15e95
Sex e male/female 111/86
Risk factor e no. (%)
Age> 75 yr. 65 (33%)
History of venous
thromboembolism e no. (%)
2 (1%)
Obesity 32 (16.2%)
Varicose veins 8 (4.1%)
Chronic heart failure 11 (5.6%)
Chronic obstructive
lung disease
7 (3.6%)
Hormone-replacement therapy 0 (0%)
2 Risk factors e no. (%) 21 (10.7%)
Chemotherapy 34 (17.3%)
Radiotherapy 11 (5.6%)
Major surgery e n (%) 195 (99.0%)
Type of surgery e n (%)
Gastrointestinal tract 134 (68%)
Female reproductive organs 21 (10.7%)
Genitourinary tract 27 (13.7%)
Lungs and/or bronchial tree 13 (6.6%)
Other 7 (3.6%)
2 Sites 17 (8.6%)
Palliative surgery e no. (%) 12/190 (6.3%)
Duration of surgery
Median 2 h 50 min
Range 20 min to 6 h
Type of anaesthesia
General 182 (93.3%)
Neuraxial 13 (6.7%)
Hospital stay,
days e median (1st, 3rd quartile)
10 (7, 14.5)
Prophylaxis information
Start of prophylaxis preoperative
(2500 IU/3500 IU), n
152 (96/56)
Start of prophylaxis postoperative
(2500 IU/3500 IU), n
45 (28/17)
Prophylactic dose used
2500/3500 IU, n/n
124/73
Duration of prophylaxis,
median (range)
12 (2, 51)
Patients receiving NSAIDs, n (%) 104 (52.8%)
NSAIDZ non-steroidal anti-inflammatory drug.
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Three of 197 patients developed a documented symptomatic
VTE: 2 patients had distal DVT, and the remaining patient
had proximal DVTcomplicated with non-fatal PE (Table 2). In
all 3 cases of symptomatic VTE, patients were at high risk but
received the 2500 IU bemiparin dose. There were no cases of
fatal PE. The incidence of thromboembolic events was lower
in the postoperative bemiparin group, but the difference
was not statistically significant (0.0% vs. 2.0%; difference,
2.0%, 95% CI, 6.2% to 5.7%, PZ 0.39). The incidence of
thromboembolic events was lower among the patients re-
ceiving bemiparin 3500 IU as compared to 2500 IU, but the
difference was not statistically significant (0% vs. 2.4%; dif-
ference, 2.4%; 95% CI, 7.2% to 3%; PZ 0.20).
Nine (4.6%) of 197 patients experienced a bleeding event
during bemiparin prophylaxis (95% CI, 2.1e8.5%). All such
events were related to the surgical wound or occurred
intraoperatively. Four events (2.0%), all of them occurring
after preoperative bemiparin dosing, were major (Table 2).
Major bleeding cases were 3 intra-abdominal bleedings
after colon surgery that required repeat surgery, and 1
surgical wound bleeding after rectal surgery requiring
transfusion of 3 units of red packed cells. There were no
cases of fatal, retroperitoneal or intracranial bleeding.
Postoperative administration showed a trend to lower
bleeding rates compared to preoperative start of prophy-
laxis, but the differences were not statistically significant
[2.2% (1 of 45) vs. 5.3% (8 of 152); difference, 3.1%; 95%
CI, 8.4% to 6.8%; PZ 0.47]. Bleeding rates did not signif-
icantly differ between 3500 and 2500 IU bemiparin doses
[5.5% (4 of 73) vs. 4.0% (5 of 124); difference, 1.5%; 95%
CI, 5% to 9.6%; PZ 0.72].
Bleeding risk was higher, but not statistically significant,
in gastrointestinal tract surgery as compared to other types
of surgery (RR, 3.8; PZ 0.19). Treatment with analgesics
and/or anti-platelet drugs was not a risk factor favouring
bleeding (RR, 0.45; PZ 0.26). Only 13 patients underwent
epidural anaesthesia. None of these patients experienced
bleeding events.
One patient with colon cancer and hepatic cirrhosis
developed moderate thrombocytopenia (56,000 platelets
per cubic millilitre) while receiving bemiparin 2500 IU for
13 days. Treatment was not discontinued and patientdid not develop further thrombotic or haemorrhagic com-
plications. One patient with gastric cancer, who had
received bemiparin 2500 IU before surgery, died 24 days
after urgery due to cardio-respiratory failure during
hospitalisation.
Postoperative administration showed a trend to a lower
incidence of total events related to VTE or bemiparin
prophylaxis compared to preoperative administration
[2.2% (1 of 45) vs. 9.9% (15 of 152); difference, 7.7%;
95% CI, 14% to 2.3%; PZ 0.11]. In addition, the number of
total events was also lower in patients treated with the
3500 IU bemiparin dose compared to 2500 IU dose [4.1%
(3 of 73) vs. 10.5% (13 of 124); difference, 6.4%; 95% CI,
13.9% to 2.1%; PZ 0.12].
Outpatient period
The median period from surgery to the first outpatient visit
was 40 days (range: 20e95). There were no cases of
symptomatic VTE or bleeding events during the period
from hospital discharge on day 10 (median) to the first
outpatient visit on day 40 (median). One patient operated
for an oesophageal neoplasm who was administered bemi-
parin 2500 IU before surgery died because of pneumonia
and sepsis 20 days after hospital discharge.
Pharmacoeconomic analysis (Pre- vs.
postoperative start of prophylaxis)
The rates of clinical complications for post- and preoper-
ative bemiparin are summarised in Table 2.
In order to calculate the cost of treatment with LMWH,
hospital stay costs, pharmacy costs and complications costs
were added.
Pharmacoeconomic results are given as costs and cost-
differences per patient administered prophylaxis for VTE
with either post- or preoperative bemiparin (Table 3). Post-
operative bemiparin provided net cost savings of V909 per
patient compared to preoperative bemiparin when costs de-
rived from treatment and complications during the 40-day
observation period were considered (V3297 vs. V4206).
Net cost savings were mainly attributable to shorter hospitalTable 2 Overall incidence of clinical events, baseline probabilities for postoperative vs. preoperative bemiparin and ranges
for clinical outcomesa
Outcome Total (NZ 197) Post-op. Bemiparin Pre-op. Bemiparin Difference (95% CI)b
n (%) (%) (%) (%)
Venous thromboembolism 3 (1.5)a 0.0 2.0 2.0 (6.2 to 5.7)
Pulmonary embolism 1 (0.5) 0.0 0.7 0.7 (7.6 to 3.7)
Deep vein thrombosis 3 (1.5) 0.0 2.0 2.0 (6.2 to 5.7)
Total bleeding 9 (4.6) 2.2 5.3 3.1 (8.4 to 6.8)
Major bleeding 4 (2.0) 0.0 2.6 2.6 (6.6 to 6.0)
Minor bleeding 5 (2.5) 2.2 2.6 0.4 (9.2 to 5.0)
Thrombocytopenia 1 (0.5) 0.0 0.7 0.7 (7.6 to 3.7)
Death from any cause 2 (1.0) 0.0 1.3 1.3 (6.8 to 4.7)
a The patient with non-fatal PE had also proximal DVT, thus the composite VTE is 3 and not 4.
b A negative difference favours postoperative bemiparin.
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complications in the postoperative bemiparin group.
Univariate sensitivity analyses showed that postopera-
tive bemiparin was cost-saving compared to preoperative
bemiparin in all the ranges tested for complications and
costs. Cost savings ranged from V475 to V1237 in the worst
and best case, respectively.
Discussion
Most patients in our study were given lower bemiparin doses
than recommended by current VTE Consensus Guidelines.3,4
Our observation is consistent with the results from a recent
report showing that the risk of VTE in cancer patients is
underestimated.17 Thus, physicians are recommended to fol-
low current VTE Consensus Guidelines,3,4 in order to estab-
lish the extent of VTE risk in their patients, and to
administer the appropriate LMWH dose (for moderate or
high risk) according to each LMWH specifications. Bemiparin
3500 IU/d administered to patients at high risk of VTE fully
prevented documented symptomatic VTE, whereas 3 high-
risk patients experienced a VTE event while receiving
2500 IU/d bemiparin dose, recommended for patients with
amoderate risk of VTE. In addition, bleeding rates did not sig-
nificantly differ between low and high bemiparin prophylac-
tic doses. Thus, no evidence supporting administration of
bemiparin 2500 IU to patients at high risk of VTE was found.
There are several factors related to prophylaxis (e.g.
pre- vs. postoperative start of prophylaxis) and anaesthetic
procedures (general vs. neuraxial anaesthesia) that could
alter bleeding rates in patients undergoing surgery. As
regards relationship between type of anaesthesia and
surgical bleeding, in a previous study with bemiparin in
orthopaedic surgery, neuraxial anaesthesia significantly
decreased operative blood loss compared to general anaes-
thesia.18 Most patients in our study did not receive neuraxial
anaesthesia, although this practice should be considered in
order to reduce blood loss in these patients. Postoperative
start of bemiparin prophylaxis 6 h after surgery is consistent
with current recommendations to minimise the risk of
spinal haematoma when neuraxial anaesthesia and throm-
boprophylaxis are used together19,20 and could be an
Table 3 Results of the cost-difference analysis in euros
(2002 values)
Variable Post-op.
bemiparin
Pre-op.
bemiparin
Differencea
Treatment costs
Hospital stay costs 3195 3898 703
Pharmacy costs 94 118 24
Complications costs
Pulmonary embolism 0 25 25
Deep vein thrombosis 0 37 37
Total bleeding 8 32 24
Thrombocytopenia 0 2 2
Death from any cause 0 94 94
Total costs, V 3297 4206 909
a A negative difference favours postoperative bemiparin pro-
phylaxis, representing cost savings.optimal measure to minimise the risk of bleeding in cancer
surgical patients, without compromising efficacy.
Postoperative bemiparin was cost-saving, and shortened
hospital stay by 2 days (mean), compared to preoperative
bemiparin cohort. This is a result of great interest for major
ambulatory surgery.21
Although the timing of the first administration of
thromboprophylaxis is controversial,22 it is recognised
that bemiparin administration started 6 h postoperatively
does not compromise efficacy, it is safe and compatible
with neuraxial anaesthesia techniques.13 On the contrary,
patients on preoperative LMWH thromboprophylaxis can
be assumed to have altered coagulation. In these patients,
needle placement should occur at least 10e12 h after the
LMWH dose.19,20 Thromboprophylaxis started less than 6 h
after surgery may increase the risk of bleeding without im-
proved efficacy.22 Initiation 12e24 h postoperatively may
be less effective than initiation at 6 h.22
This study has several methodological limitations as
follows: its retrospective nature, the relatively small sam-
ple size and low incidence of clinical events, the absence
of a comparative group and the selection on the timing and
dose of bemiparin, which was decided by the surgeons
according to standard clinical practice. However, the results
of this observational study should be interpreted in the
setting of normal clinical practice. These types of studies
add information that is not available in randomised con-
trolled trials where exclusion criteria, limited sample size
and use in specific clinical situation lead to significant loss
of useful pragmatic data.23 Therefore, we were able to
assess the ‘‘real life’’ effect and use of bemiparin prophylaxis
in cancer patients.
In conclusion, many cancer patients are still poorly
assessed for risk of VTE. It may be simpler in this group to
consider all to be at high risk given the low incidence and
generally benign nature of bleeding complications. Bemi-
parin 3500 IU/d is associated with a lower incidence of VTE
without significant increase in complications as compared
with bemiparin 2500 IU/d. Postoperative bemiparin prophy-
laxis seems to be as effective and safer than preoperative
start of prophylaxis and it also seems to be cost-saving. Fur-
ther prospective clinical studies are needed to fully address
this issue.
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Appendix
The members of the Bemiparin Cooperative Study Group
in Surgery for Cancer (all in Spain) were as follows:
Dr. J. Altimiras, Hospital General de Catalun˜a, Sant Cugat
Bemiparin thromboprophylaxis in cancer surgery 119del Valle´s, Barcelona (currently working for Corporacio´
Sanitaria Parc Taulı´, Sabadell, Barcelona); Dr. I. Larruzea,
Dr. F. Ramos, Hospital de San Eloy, Barakaldo, Vizcaya; Dr. I.
Portal, Hospital Mutua de Terrassa, Barcelona; Dr. F. Ara-
nzadi, Hospital del Bidasoa, Iru´n, Guipu´zcoa; Dr. I. de Diego,
Clı´nica Santa Marı´a de la Asuncio´n, Tolosa, Guipu´zcoa.
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